- Umbilical vein varix
- Timing of Cranial Markers in Open NTD
- Real world experience Open Neural tube defect and Brain Signs
- Real world experience First Trimester Megacystis – Management
- Real world experience Fetal Megacystis
- Abnormal facial profile
- Azygous Vein & ARSA
- Blakes Pouch Cyst
- Absent nasal bone (ANB)
- Choroid plexus cysts
- Chronic placental abruption
- Fetal Alcohol Syndrome
- Placenta-First Risk Stratification
Placenta First Risk Stratification
• “Placental impact” reflects how often CPM causes real placental dysfunction even when the fetus is euploid.
• “Typical mechanism” helps interpret NIPT and CVS discordance.
• “Clinical risk” is about pregnancy course, not just fetal karyotype.
High placental risk chromosomes (placenta-limited disease dominates)
| Chromosome | CPM frequency | Typical mechanism | Placental impact | Common outcomes | Clinical implication |
|---|---|---|---|---|---|
| 16 | Very high | Meiotic trisomy → rescue | Severe | Early FGR, IUFD, preeclampsia | Treat as high-risk placental insufficiency even if amnio normal |
| 22 | High | Meiotic or early mitotic | Severe | FGR, abnormal Dopplers | Close surveillance mandatory |
| 15 | Moderate–high | Meiotic trisomy → rescue | Moderate | UPD syndromes, FGR | Consider UPD testing + growth surveillance |
| 7 | Moderate | Meiotic trisomy → rescue | Moderate | Silver–Russell phenotype, FGR | Normal karyotype ≠ low risk |
| 14 | Moderate | Meiotic rescue | Moderate | Temple / Kagami–Ogata syndromes | Placental + imprinting risk |
Intermediate placental risk chromosomes
| Chromosome | CPM frequency | Typical mechanism | Placental impact | Common outcomes | Clinical implication |
|---|---|---|---|---|---|
| 18 | High | Mitotic or meiotic | Variable | CPM common, placental dysfunction possible | Positive NIPT often CPM; monitor growth |
| 13 | Moderate | Meiotic | Variable | Structural anomalies if fetal | Placental risk secondary to fetal disease |
| 8 | Moderate | Mitotic mosaicism | Mild–moderate | Variable FGR | Doppler-guided follow-up |
| 9 | Moderate | Mitotic | Mild–moderate | Often benign | Reassure if growth normal |
Low placental risk chromosomes (often well tolerated)
| Chromosome | CPM frequency | Typical mechanism | Placental impact | Common outcomes | Clinical implication |
|---|---|---|---|---|---|
| 21 | Moderate | Mitotic CPM | Mild | Usually normal growth | False-positive NIPT often benign |
| 20 | Low–moderate | Mitotic | Mild | Rare FGR | Minimal intervention if isolated |
| X | Variable | Mitotic mosaicism | Mild | Usually compensated placenta | Counsel separately for fetal effects |
Key patterns
1. Placenta-toxic chromosomes
• 16, 22, 15, 7
These are the chromosomes where: A “normal amniocentesis” does not mean a low-risk pregnancy.
2. NIPT interpretation nuance
• NIPT positive for T16 or T22 → think placental disease first, fetus second
• NIPT positive for T21 → fetal risk dominates, placental risk usually mild
A positive NIPT followed by a normal fetus can still predict:
• Early FGR
• Abnormal uterine artery Doppler
• Late IUFD if not monitored
The obstetric risk of CPM is chromosome-dependent, with trisomies 16, 22, 15, and 7 acting primarily as placental diseases rather than fetal genetic disorders.